Study on the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen in CD19-targeting CAR-T Therapies.

This article provides information about a clinical trial in China that is currently recruiting participants. The trial aims to evaluate the effectiveness of a treatment regimen for patients with B-cell acute lymphoblastic leukemia and B-cell lymphoma refractory. The regimen includes mitoxantrone hydrochloride liposome injection-based bridging therapy, fludarabine-based chemotherapy, and CD19 CAR-T cells. The study will assess various factors such as overall response rate, complete response rate, in vivo expansion and survival of CD19 CAR-T cells, and the incidence of treatment-related adverse events. The goal of the trial is to improve patient outcomes and provide effective CAR-T cell therapy for hematologic malignancies. [Extracted from the article]